Treatment Algorithm | CroFab.com

Get familiar with the algorithm, and let it help guide you in the event of a snakebite

The unified treatment algorithm is a comprehensive procedure based on expert recommendations for proper treatment in the event of a pit viper snakebite.

Eric Lavonas, MD, FACEP, FACMT Emergency Medicine & Medical Toxicology

Hear From the Lead Author of the Treatment Algorithm

“When treating a snakebite, there is a small window to provide care, and the importance of every decision is magnified.”

Listen now

Interactive Treatment Algorithm

The interactive treatment algorithm can serve as a guide in preparation of and during snakebite envenomation.

LAUNCH ALGORITHM

Full Treatment Algorithm Poster

Be prepared at every stage of envenomation management with guidance from the algorithm poster.

Download PDF >

Full Treatment Algorithm Research Article

Read the clinical research behind the consensus treatment algorithm for the management of North American pit viper envenomation.

Download PDF >

This information is adapted from general advice from a panel of US snakebite experts convened in May 2010. No algorithm can anticipate all clinical situations. Other valid approaches exist, and deviations from this information based on individual patient needs, local resources, local treatment guidelines, and patient preferences are expected. This algorithm is not intended to represent a standard of care. For more information, please see the accompanying manuscript, available at www.biomedcentral.com.

Watch Dr. Eric Lavonas break down the reasoning behind the unified treatment algorithm.

Did You Know?

It has been estimated that 7,000-8,000 people are bitten by venomous snakes per year. The number of morbidities can be decreased with preparation for aggressive and immediate medical intervention.¹

Review the full treatment algorithm.

Launch interactive guide >

Reference:

1. Frequently Asked Questions. Department of Wildlife Ecology and Conservation website. Ufwildlife.ifas.ufl.edu/venomous_snake_faqs.shtml. Accessed May 23, 2018.

Algorithm

Review the expert consensus for managing pit viper snakebites.

Dosing + Administration

Learn how to dose CroFab® to gain and continue control of pit viper envenomation.

Patient Experiences

Watch testimonials and review case studies to learn from patient experiences.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Do not administer CroFab® to patients with a known history of hypersensitivity to any of its components, or to papaya or papain unless the benefits outweigh the risks and appropriate management for anaphylactic reactions is readily available.

WARNINGS AND PRECAUTIONS

Coagulopathy: In clinical trials, recurrent coagulopathy (the return of a coagulation abnormality after it has been successfully treated with antivenin), characterized by decreased fibrinogen, decreased platelets, and elevated prothrombin time, occurred in approximately half of the patients studied; one patient required re-hospitalization and additional antivenin administration. Recurrent coagulopathy may persist for 1 to 2 weeks or more. Patients who experience coagulopathy due to snakebite should be monitored for recurrent coagulopathy for up to 1 week or longer. During this period, the physician should carefully assess the need for re-treatment with CroFab® and use of any type of anticoagulant or anti-platelet drug.

Hypersensitivity Reactions: Severe hypersensitivity reactions may occur with CroFab®. In case of acute hypersensitivity reactions, including anaphylaxis and anaphylactoid reactions, discontinue infusion and institute appropriate emergency treatment. Patients allergic to papain, chymopapain, other papaya extracts, or the pineapple enzyme bromelain may also have an allergic reaction to CroFab®. Follow-up all patients for signs and symptoms of delayed allergic reactions or serum sickness (e.g., rash, fever, myalgia, arthralgia).

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥ 5% of subjects) reported in the clinical studies were urticaria, rash, nausea, pruritus and back pain. Adverse reactions involving the skin and appendages (primarily rash, urticaria, and pruritus) were reported in 12 of the 42 patients. Two patients had a severe allergic reaction (severe hives and a severe rash and pruritus) following treatment and one patient discontinued CroFab® due to an allergic reaction. Recurrent coagulopathy due to envenomation and requiring additional treatment may occur.

Please see full Prescribing Information.

INDICATION

CroFab® Crotalidae Polyvalent Immune Fab (Ovine) is a sheep-derived antivenin indicated for the management of adult and pediatric patients with North American crotalid envenomation. The term crotalid is used to describe the Crotalinae subfamily (formerly known as Crotalidae) of venomous snakes which includes rattlesnakes, copperheads and cottonmouths/water moccasins.

BTG and the BTG roundel logo are registered trademarks of BTG International Ltd.
CroFab ^® is a registered trademark of BTG International Inc.
TIME IS TISSUE^® is a trademark of Protherics Medicines Development Ltd., a BTG International group company. BTG Specialty Solutions Center^™ is a trademark of BTG International Ltd. SnakeBite911 and the snakehead logo are trademarks of Protherics UK Ltd. Apple and the Apple logo are trademarks of Apple Inc., registered in the U.S. and other countries. ‭Google Play and the Google Play logo are trademarks of Google Inc.

© 2019 BTG International Inc. All rights reserved.
US-CRF-1900219 October 2019

To report suspected adverse reactions, contact BTG at
1-877-377-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

BTG Specialty Solutions Center^TM

	1-844-293-0007 (Voice)
	1-877-626-9910 (Fax)

24-hour Medical Information:

1-877-377-3784